1. Home
  2. CELH vs TLX Comparison

CELH vs TLX Comparison

Compare CELH & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CELH
  • TLX
  • Stock Information
  • Founded
  • CELH 2004
  • TLX 2015
  • Country
  • CELH United States
  • TLX Australia
  • Employees
  • CELH N/A
  • TLX N/A
  • Industry
  • CELH Beverages (Production/Distribution)
  • TLX Biotechnology: Pharmaceutical Preparations
  • Sector
  • CELH Consumer Staples
  • TLX Health Care
  • Exchange
  • CELH Nasdaq
  • TLX Nasdaq
  • Market Cap
  • CELH 7.5B
  • TLX 6.0B
  • IPO Year
  • CELH N/A
  • TLX N/A
  • Fundamental
  • Price
  • CELH $33.65
  • TLX $17.24
  • Analyst Decision
  • CELH Buy
  • TLX Strong Buy
  • Analyst Count
  • CELH 17
  • TLX 1
  • Target Price
  • CELH $45.53
  • TLX $22.00
  • AVG Volume (30 Days)
  • CELH 8.9M
  • TLX 31.9K
  • Earning Date
  • CELH 05-06-2025
  • TLX 01-01-0001
  • Dividend Yield
  • CELH N/A
  • TLX N/A
  • EPS Growth
  • CELH N/A
  • TLX 798.14
  • EPS
  • CELH 0.45
  • TLX 0.09
  • Revenue
  • CELH $1,355,630,000.00
  • TLX $484,687,790.00
  • Revenue This Year
  • CELH $34.11
  • TLX N/A
  • Revenue Next Year
  • CELH $17.00
  • TLX N/A
  • P/E Ratio
  • CELH $74.24
  • TLX $190.59
  • Revenue Growth
  • CELH 2.85
  • TLX 55.85
  • 52 Week Low
  • CELH $21.10
  • TLX $14.01
  • 52 Week High
  • CELH $98.85
  • TLX $30.36
  • Technical
  • Relative Strength Index (RSI)
  • CELH 64.01
  • TLX N/A
  • Support Level
  • CELH $33.74
  • TLX N/A
  • Resistance Level
  • CELH $32.08
  • TLX N/A
  • Average True Range (ATR)
  • CELH 1.78
  • TLX 0.00
  • MACD
  • CELH 0.51
  • TLX 0.00
  • Stochastic Oscillator
  • CELH 79.66
  • TLX 0.00

About CELH Celsius Holdings Inc.

Celsius Holdings plays in the energy drink subsegment of the global nonalcoholic beverage market, with 96% of revenue concentrated in North America. Celsius' products contain natural ingredients and a metabolism-enhancing formulation, appealing to fitness and active lifestyle enthusiasts. The firm's portfolio includes its namesake Celsius Originals beverages, Celsius Essentials line (containing aminos), and Celsius On-the-Go powder packets. Celsius dedicates its efforts to branding and innovation, while it utilizes third parties for the manufacturing, packaging, and distribution of its products. In 2022, Celsius forged a 20-year distribution agreement with PepsiCo, which holds an 8.5% stake in the business.

About TLX Telix Pharmaceuticals Limited American Depositary Shares

Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.

Share on Social Networks: